Whalen Wealth Management Inc. Sells 740 Shares of Eli Lilly and Company (NYSE:LLY)

Whalen Wealth Management Inc. lowered its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 72.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 284 shares of the company's stock after selling 740 shares during the quarter. Whalen Wealth Management Inc.'s holdings in Eli Lilly and Company were worth $234,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the stock. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $43,000. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company during the fourth quarter worth about $48,000. Highline Wealth Partners LLC raised its position in Eli Lilly and Company by 53.3% in the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after purchasing an additional 24 shares during the period. Capital A Wealth Management LLC acquired a new position in Eli Lilly and Company during the 4th quarter worth about $63,000. Finally, Bellwether Advisors LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $66,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $8.33 during mid-day trading on Tuesday, reaching $778.97. The company had a trading volume of 2,773,370 shares, compared to its average volume of 3,666,228. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock has a market cap of $738.26 billion, a PE ratio of 63.38, a P/E/G ratio of 1.11 and a beta of 0.41. The company has a 50-day moving average price of $780.81 and a two-hundred day moving average price of $800.36.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.58 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.77%. Eli Lilly and Company's payout ratio is 48.82%.

Analyst Ratings Changes

LLY has been the subject of several recent research reports. UBS Group decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, June 7th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, Guggenheim restated a "buy" rating and issued a $936.00 price objective on shares of Eli Lilly and Company in a research report on Friday. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,011.79.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.